OVB — Ovoca Bio Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- £1.02m
- -£1.17m
Annual cashflow statement for Ovoca Bio, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.37 | -5.47 | -5.61 | -4.7 | -0.746 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -0.228 | -0.092 | 0.336 | 4.3 | 0 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.418 | 1.11 | -0.419 | 1.22 | -0.46 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.11 | -4.38 | -5.16 | 1.11 | -1.21 |
| Capital Expenditures | -0.01 | -0.014 | 0 | — | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 7.59 | -0.053 | 1.51 | -0.049 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 7.58 | -0.067 | 1.51 | -0.049 | 0 |
| Financing Cash Flow Items | -4.09 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.09 | 0 | 0.9 | -0.879 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.733 | -4.15 | -2.89 | -0.366 | -0.831 |